Johnson & Johnson recently announced plans to invest more than $2 billion in a new manufacturing facility in North Carolina. The company plans to build a state-of-the-art biologics manufacturing facility in Wilson, North Carolina, to expand the production of its pipeline of innovative biologics. The expansion supports J&J’s broader plan to advance more than 70…
Roche opens pharma R&D facility in Switzerland
Roche recently announced it opened its latest Pharma Research and Early Development (pRED) Center in Basel Switzerland. The new facility is equipped with cutting-edge technologies and houses around 1,000 laboratory and office workspaces, according to the company. It is located at the company’s global headquarters and brings together teams of scientists and researchers to accelerate…
Lilly expands manufacturing footprint in Ireland
Eli Lilly and Co. recently announced that it’s spending $1 billion to expand its Limerick, Ireland, manufacturing site. The goal of the expansion, announced Sept. 12, is to increase the production of biologic active ingredients, including those for the company’s recently approved treatment for early symptomatic Alzheimer’s disease. The company announced in July that the…
Eugia Pharma receives OAI classification from FDA following sterile production inspections
Eugia Pharma Specialties’ manufacturing hub in India has received an FDA warning letter based on inspections of its facility. The new warning letter is tied to previous warnings about the company’s Unit III Formulation manufacturing facility. The unit makes terminally sterilized products. Eugia’s Hyderabad, India-based facility received an official action indicated (OAI) status notice in…
Pfizer opens expanded APIs plant in Singapore
Pfizer recently opened an extension of its highly automated active pharmaceutical ingredient (API) manufacturing facility in Tuas Biomedical Park in Singapore. The 429,000 ft2 expansion cost SGD $1 billion (U.S. $745 million), according to a July 23 news release from the Singapore Economic Development Board. Pfizer has passed final performance qualification checks at the facility…
Sanofi will build a new insulin plant in Germany
Sanofi recently announced that it will spend €1.3 billion ($1.4 billion) over the next five years to build a new insulin production facility at its BioCampus in Frankfurt Höchst, Germany. The 36,000 m2 (equivalent to nearly 388,000 ft2) facility will replace existing insulin production plants. Paris-based Sanofi says several hundred highly qualified specialists will work…
Lotte Biologics is spending billions on new Korean plant
Lotte Biologics recently held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International City. The ceremony marked a step toward becoming a global top 10 CDMO, Lotte said in a news release. Lotte’s new campus comes as part of its “Bio & Wellness” business focus. It features an investment…
Sanofi, Novartis among Time’s most sustainable companies
Pharma giants Sanofi and Novartis came in at No. 7 and 17, respectively, in Time magazine’s “Most Sustainable Companies of 2024” rankings. Overall, nearly 40 of the 500 companies on the list fell under the category of Chemicals, Drugs & Biotechnology. Other large pharma companies making it into the top half of the 500 included…
Veranova to spend $30M on Massachusetts facility
Veranova recently announced that it will invest $30 million in its Devens, Massachusetts facility to expand its antibody-drug conjugate (ADC) and highly potent compound development and manufacturing capabilities The Wayne, Pennsylvania–based company — a specialist in making active pharmaceutical ingredients — said the investment in the Devens plant will build upon the site’s existing development…
Novo Nordisk invests $4.1B to expand manufacturing operations in North Carolina
Novo Nordisk today announced plans to invest $4.1 billion to build a new manufacturing facility in North Carolina. The Denmark-based company will build a second fill and finishing manufacturing facility in Clayton, North Carolina, to grow its ability to produce current and future injectable treatments for people with obesity and other serious chronic diseases. Novo…